Cardiac Amyloidosis: On the Road

Join us for a Cardiac Amyloidosis symposium in your region.

Cardiac Amyloidosis: Virtual On the Road in Houston 

TitleCardiac Amyloidosis: From Missed and Undiagnosed, to Common and Treatable
Saturday, Oct. 24
8:30 am to Noon (CDT)
Program Director: Mouaz Al-Mallah, MD, FASNC

 ​Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.25* AMA PRA Category 1 Credits™​ or 3.25* ARRT Category A CE credits 

*Credits subject to change
Time Central Time Title Speaker
8:30 am - 8:35 am  Welcome Mouaz Al-Mallah, MD
8:35 am - 9:00 am  ATTR Cardiac Amyloidosis: Clinical Presentation and Outcomes Juan C. Lopez-Mattei, MD
9:00 am - 9:20 am  The Role of Echocardiography and Cardiac MRI in Suspected Cardiac Amyloidosis Faisal Nabi, MD
9:20 am - 9:45 am  PYP Imaging: Diagnostic Accuracy and Pitfalls Brett Sperry, MD
9:45 am - 10:00 am  Cardiac PET in Suspected Cardiac Amyloidosis Mouaz Al-Mallah, MD
10:00 am - 10:20 am  Management of ATTR Amyloidosis Barry Trachtenberg, MD
10:20 am - 10:40 am  Panel Discussion  
10:40 am - 11:00 am  Break  
11:00 am - 11:45 am
 Case Presentations
  1. Mohammad Chamsi Pasha, DO
  2. Ali Agha, MD
  3. Alpana Senapati, DO
Mouaz Al-Mallah, MD
Faisal Nabi, MD
Mahwash Kassi, MD
JOhn Mahmarian, MD
Barry Trachtenberg, MD
11:45 am - Noon  Final Remarks Mouaz Al-Mallah, MD
This program is jointly sponsored by the American Society of Nuclear Cardiology and Houston Methodist.


Cardiac Amyloidosis: Virtual On the Road in South Florida 

Title: South Florida Cardiac Amyloid Symposium
Wake up and Look Around
Towards Early Recognition, Diagnosis and Treatment of Cardiac Amyloidosis

Saturday, Oct. 31
8:00 am to Noon (EDT)
Program Director: 
David Wolinsky, MD, MASNC

Fee: ​Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.25* AMA PRA Category 1 Credits™​ or 3.25* ARRT Category A CE credits  

*Credits subject to change

Eastern Time Title Speaker
8:00 am  Welcome, Introduction and Knowledge Questions David Wolinsky, MD
8:05 am  Overview of Amyloidosis Frederick Ruberg, MD
8:40 am  Diagnosis of Cardiac Amyloid in 2020: Guideline Recommendations Prem Soman, MD, PhD
9:15 am  Management Strategies David Wolinsky, MD
9:50 am  Panel Discussion
10:15 am - 10:30 am  Break  
10:30 am - 11:30 am
 Case Based Learning
  • Amyloid and Aortic Stenosis
  • I Thought it was Amyloid but Not Sure About the Tc-99m PYP Scan
  • Amyloid and Heart Transplant

 Abdullah Sarkar, MD – Presenter
David Wolinsky, MD – Discussant

Syed Bukhari, MD
Prem Soman MD, PhD
Diana Miranda, MD – Presenter
Viviana Navas, MD – Discussant

11:30 am - Noon  What the Future Holds and Closing Remarks David Wolinsky, MD


Register for upcoming webinars and view our extensive archives and portfolio of online education available for CME/CE credits.

The Cardiac Amyloidosis: On the Road programs will:
  • Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM. 
  • Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM. 
  • Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.  
  • Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings. 
  • Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.
Participants of these programs will be able to:
  • Describe amyloidosis, including specific types, cardiac features and disease burden.
  • Identify barriers to identification and diagnosis of patients suspected of ATTR.
  • Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).
  • Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis. 
  • Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report. 
  • Demonstrate understanding of current treatments for patients with ATTR-CM.

If you have any questions about registration, please contact

These programs are supported by educational grants from Pfizer.

More Cardiac Amyloidosis Resources